FOI Request
- Disclosure ID
- FOI/02119
- Request Date
- January 3, 2018
- Subject
- Lynch Syndrome - Colorectal Cancer
- Description
FOI questions
- Do you test newly diagnosed bowel cancer patients in your trust (either contracted or referred) for molecular features of Lynch syndrome using either immunohistochemistry or microsatellite instability testing?
- Yes – all bowel cancer patients, as per DG 27 NICE guidance
- Yes – everyone under the age of 70
- Yes – everyone under the age of 50
- Yes – according to family history of the disease
- No
- Other
- If yes, at what stage does this testing take place?
- Pre-treatment i.e. at diagnosis (on a biopsy of the tumour)
- Post treatment i.e. test is carried out on the tumour resection specimen only.
- Not applicable
- Is this test carried out as a reflex test i.e. automatically or upon referral?
- Reflex
- Referral via MDT
- Referral via Genetics Centre
- Referral via GP
- Other (please explain)
- Not applicable
- In their published adoption support resource NICE suggest identifying a named ‘clinical champion’ within each colorectal multidisciplinary team to effectively implement testing people for molecular features for Lynch syndrome. Is this established in your trust?
- Yes, Gastroenterologist
- Yes, Colorectal Surgeon
- Yes, Oncologist
- Yes, Clinical Geneticist
- Other (please explain)
- No
- Do you audit diagnostic outcomes within your trust to ensure that every patient is tested for molecular features for Lynch syndrome?
- Yes, as part of private audit
- Yes, and the data is publicly released
- No
- Have you had to submit a business case for funding in order to effectively implement this new guidance?
- Yes, and additional funding was provided fully/partially as requested. Please provide information.
- Yes, but no additional funding was provided. Please provide information on why.
- No please provide information on why.
- If no such testing is in place, do you have information on whether there are any plans to introduce molecular testing for Lynch syndrome as per NICE guidance?
- What are the main barriers you have faced if no molecular testing or only selected testing is performed? Please specify.
- Financial
- Policy
- Awareness of current guidance
- Staff resources
- Other (please specify)
- Response
-
- Yes – all bowel cancer patients, as per DG 27 NICE guidance
- Yes – everyone under the age of 70
- Yes – everyone under the age of 50
- Yes – according to family history of the disease
- If yes, at what stage does this testing take place?
- Pre-treatment i.e. at diagnosis (on a biopsy of the tumour)
- Is this test carried out as a reflex test i.e. automatically or upon referral?
- Reflex
- In their published adoption support resource NICE suggest identifying a named ‘clinical champion’ within each colorectal multidisciplinary team to effectively implement testing people for molecular features for Lynch syndrome. Is this established in your trust?
- No
- Do you audit diagnostic outcomes within your trust to ensure that every patient is tested for molecular features for Lynch syndrome?
- Yes, as part of private audit
- Have you had to submit a business case for funding in order to effectively implement this new guidance?
- Yes, and additional funding was provided when required.
- If no such testing is in place, do you have information on whether there are any plans to introduce molecular testing for Lynch syndrome as per NICE guidance?
- N/A
- What are the main barriers you have faced if no molecular testing or only selected testing is performed? Please specify.
- N/A
-